Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

Name: Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9
Published: 2007
License: Public Domain

GlaxoSmithKline · 2007

ClinicalTrials.gov · Datasets · License: Public Domain · 2007

Open Source ↗

diphtheria immunogenicity persistence

acellular pertussis, tetanus, diphtheria, persistence, immunogenicity, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

Related documents